Vintafolide

DRUG5 trials

Sponsors

Endocyte

Conditions

Adenocarcinoma of the LungAdvanced CancerEndometrial CancerOvarian CancerSolid Tumor

Phase 1

A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)

TerminatedNCT01688791

EndocyteAdvanced Cancer

Start: 2012-12-31End: 2014-09-30Updated: 2015-02-10

A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)

TerminatedNCT02049281

EndocyteSolid Tumor

Start: 2014-02-28End: 2014-05-31Updated: 2015-02-10

Phase 2

Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

CompletedNCT00507741

EndocyteEndometrial Cancer, Ovarian Cancer

Start: 2007-08-31End: 2009-04-30Updated: 2015-01-07

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

CompletedNCT00511485

EndocyteAdenocarcinoma of the Lung

Start: 2007-08-31End: 2009-11-30Updated: 2015-02-27

Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)

CompletedNCT00722592

EndocyteOvarian Cancer

Start: 2008-09-30End: 2012-12-31Updated: 2015-01-07

Related Papers

Real-time identification of tumor lesions and response to vintafolide treatment.

Journal of Clinical Oncology2014-05-20

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

2014-04-0170 citations